Skip to main content
. Author manuscript; available in PMC: 2017 Oct 16.
Published in final edited form as: Br J Haematol. 2015 Dec 2;172(4):535–544. doi: 10.1111/bjh.13855

Table II.

Primary and Secondary Outcomes

Outcomes N (%)
Best Response
 CR 17 (52)
 PR 6 (18)
 PD 8 (24)
 SD 2 (6)
Proceeded to HDT/SCT
 No 18 (55)
 Yes 15 (45)
Probability
Progression-free survival
 100 days 82 (95% CI, 64–91)
 6 months 67 (95% CI, 48–80)
 1 year 48 (95% CI, 31–64)
 2 years 39 (95% CI, 21–57)
Overall survival
 100 days 91 (95% CI, 74–97)
 6 months 82 (95% CI, 64–91)
 1 year 67 (95& CI, 48–80)
 2 years 60 (95% CI, 39–76)

CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; HDT/SCT, high dose therapy/stem cell transplantation.